Therefore, the treatment with senolytics may not be able to reverse the loss of chondrogenic potential in PDL9
It should be used within a specific timeframe as advised by your pharmacist, typically around 30 days
This regulatory role of BPC 157 (BPC 157/ Egr1 ) may be related to other BPC 157 interactions including BPC 157/ Akt1 (elevated Akt1 expression in stroke rats, but unchanged expression in inferior caval vein ligatedrats (Vukojevic et al., 2018)), BPC 157/ Kras , BPC 157/ Src , BPC 157/ Foxo , BPC 157/ Srf , BPC 157/ Vegfr2 , BPC 157/ Nos3 , and BPC 157/ Nos1
One study evaluated 15mg/kg GHK-Cu given three times weekly for 3 months (treatment started in 4-month-old mice and given until 7 months of age)
10.3748/wjg.v24.i48.5462 18 DuzelA.VlainicJ.AntunovicM.MalekinusicD.VrdoljakB.SamaraM.et al (2017)